Physician profile
Cheryl L Wright
NPI 1558587766
$2,423.70
in general payments reported to CMS, 2019-2025
28 companies · $667 in 2025
The $667 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $686 · 2023: $405 · 2024: $665 · 2025: $667.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,738.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,737.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $585.61 | 2023-2025 | |
| Astrazeneca Pharmaceuticals Lp | $245.98 | 2022-2023 | Fasenra, Tezspire |
| Kaleo, INC. | $216.25 | 2022-2023 | Auvi-Q |
| Collegium Pharmaceutical, INC. | $170.45 | 2023-2024 | Xtampza, Belbuca |
| Biotronik Nro, INC. | $149.76 | 2025 | Prospera |
| Regeneron Healthcare Solutions, INC. | $108.11 | 2022 | |
| Pfizer INC. | $100.16 | 2024-2025 | |
| Ipsen Biopharmaceuticals, INC | $86.01 | 2024-2025 | Dysport |
| Bioventus LLC | $70.93 | 2024-2025 | Durolane |
| Abbott Laboratories | $66.11 | 2023-2024 | Proclaim, Eterna |
| Medtronic, INC. | $55.02 | 2025 | Kyphon Express II Kyphopak Tray, Inceptiv |
| Vertex Pharmaceuticals Incorporated | $52.38 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $52.00 | 2022-2023 | |
| Mml US, INC. | $51.81 | 2025 | Reactiv8 |
| Mylan Specialty L.P. | $48.35 | 2023 | Yupelri |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nalu Medical, INC. | $46.95 | 2023 | Nalu Neurostimulation System |
| Atricure, INC. | $44.58 | 2023 | |
| Glaxosmithkline, LLC. | $40.97 | 2022-2023 | Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $33.40 | 2022 | |
| Biocryst US Sales Co., LLC | $31.64 | 2022 | |
| Genzyme Corporation | $30.60 | 2022-2023 | |
| Genentech USA, INC. | $23.75 | 2022 | |
| Boston Scientific Corporation | $22.26 | 2024 | |
| Blueprint Medicines Corporation | $22.24 | 2022 | |
| Nevro Corp. | $21.08 | 2024 | Senza |
| Averitas Pharma INC. | $20.58 | 2024 | Qutenza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.23 | 2025 | Relistor |
| Alk-Abello, INC | $12.49 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheryl Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.